FEVR Tag

03 May

Posted at 21:58h in News by

Data presented on promising activity of Noregen™, first potential regenerative therapy for retinal diseasesFollows 1Q2022 U.S. FDA and EU EMA Orphan Drug Designation (ODD) for Noregen™ in Familial Exudative Vitreoretinopathy (FEVR)    May 3, 2022, Denver, CO and Rochester, MI – Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company...

27 Jan

Posted at 17:19h in News by

A Novel Regenerative Therapy For The Treatment Of Familial Exudative Vitreoretinopathy (FEVR)  First potential FEVR therapy to obtain U.S. Food and Drug Administration Orphan Drug DesignationFollows Orphan Medicinal Product Designation by European Commission based European Medicines Agency Committee for Orphan Medicinal Products Positive Opinion   January 27, 2022,...